Liminatus Pharma (LIMN) Return on Capital Employed (2025 - 2026)

Liminatus Pharma (LIMN) posted Return on Capital Employed of 307.33% for Q1 2026, up 870.38% sequentially from 31.67% in Q4 2025.

Liminatus Pharma (LIMN) Return on Capital Employed (2025 - 2026) Analysis & Trends

Liminatus Pharma has reported Return on Capital Employed for 2 years, with the latest figure at 307.33% in Q1 2026.

Quarterly Return on Capital Employed changed N/A year-over-year to 307.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 307.33% (changed N/A YoY) and the FY2025 annual result came in at 40.45%, changed N/A from the prior year.
Return on Capital Employed rose to 307.33% in Q1 2026 per LIMN's latest filing, from 31.67% in the prior quarter.
Over five years, Return on Capital Employed peaked at 307.33% in Q1 2026 and troughed at 31.67% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn	10.74%
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn	26.09%
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn	-6.85%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-50.93%
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	7.88%
10	Liminatus Pharma	261.83 Mn	261.83 Mn	-	-7,188.34%

Download Data